Advances in the management of low-grade gliomas

Current Oncology Reports

Volumn 16, Issue 8, 2014, Pages

  Nageswara Rao, Amulya A ^a   Packer, Roger J ^b,c  

^a MAYO CLINIC   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Antiangiogenic agents; BRAF fusion; BRAF mutations; Chemotherapy; Diffuse astrocytoma; Low grade astrocytoma; Molecular targeted therapy; Pediatric low grade glioma; PI3K AKT mTOR pathway; Pilocytic astrocytoma; Radiation; Ras Raf MEK pathway; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCARBAZINE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; TEMOZOLOMIDE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; EVENT FREE SURVIVAL; GLIOMA; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PROGRESSION FREE SURVIVAL; REVIEW; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CLINICAL TRIAL (TOPIC); PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84902037967     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0398-9     Document Type: Review

References (88)

1. Wisoff JH et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011;68(6):1548-54. Discussion 1554-5.
2. Louis DN et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. (Pubitemid 47103521)
3. Rodriguez FJ et al. Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol. 2013;8:361-79.
4. Bandopadhayay P, et al. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014;61(7):1173-9. A large study of of 4,040 children showed that pediatric LGGs are associated with excellent long term survival with low likelihood of pedaitric LGG related death in adult survivors thereby emphazising the need for treatment strategies that will minimize long term sequelae.
5. Mirow C et al. Children <1 year show an inferior outcome when treated according to the traditional LGG treatment strategy: a report from the German multicenter trial HIT-LGG 1996 for children with low grade glioma (LGG). Pediatr Blood Cancer. 2014;61(3):457-63.
6. Qaddoumi I, Sultan I, Gajjar A. Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database. Cancer. 2009;115(24):5761-70.
7. Youland RS et al. Prognostic factors and survival patterns in pediatric low-grade gliomas over 4 decades. J Pediatr Hematol Oncol. 2013;35(3):197-205.
8. Terashima K et al. Long-term outcome of centrally located low-grade glioma in children. Cancer. 2013;119(14):2630-8.
9. Fisher PG et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer. 2008;51(2):245-50. (Pubitemid 351874420)
10. Gnekow AK et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro-Oncology. 2012;14(10):1265-84.
11. Pollack IF et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg. 1995;82(4):536-47.
12. Gajjar A et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(8):2792-9. (Pubitemid 27330005)
13. Steinbok P et al. Neurological morbidity of surgical resection of pediatric cerebellar astrocytomas. Childs Nerv Syst ChNS Off J Int Soc Pediatr Neurosurg. 2013;29(8):1269-75.
14. Mishra KK et al. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro-Oncology. 2006;8(2):166-74. (Pubitemid 46542661)
15. Fisher BJ et al. Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys. 2001;51(3):704-10.
16. Merchant TE et al. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(22):3598-604.
17. Armstrong GT et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro-Oncology. 2011;13(2):223-34.
18. Grill J et al. Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol. 1999;45(3):393-6. (Pubitemid 29120046)
19. Epstein MA et al. Vascular malformation with radiation vasculopathy after treatment of chiasmatic/hypothalamic glioma. Cancer. 1992;70(4):887-93.
20. Merchant TE et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(22):3691-7.
21. Ruge MI et al. Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: longterm outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(31):4151-9.
22. Kirsch DG, Tarbell NJ. New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy. Pediatr Blood Cancer. 2004;42(5):461-4. (Pubitemid 38524479)
23. Packer RJ et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-54. (Pubitemid 27187674)
24. Packer RJ et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(5):850-6. (Pubitemid 23146078)
25. Gururangan S et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(13):2951-8. (Pubitemid 34728889)
26. Massimino M et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(20):4209-16. (Pubitemid 35191023)
27. Massimino M et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neuro-Oncol. 2010;100(1):65-71.
28. Sardi I et al. Successful treatment with a low-dose cisplatin-etoposide regimen for patients with diencephalic syndrome. J Neuro-Oncol. 2012;109(2):375-83.
29. Laithier V et al. Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(24):4572-8. (Pubitemid 46594029)
30. Prados MD et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neuro-Oncol. 1997;32(3):235-41. (Pubitemid 27077974)
31. Mishra KK et al. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neuro-Oncol. 2010;100(1):121-7.
32. Bouffet E et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(12):1358-63. This phase II study demonstrated that vinblastine can be considered as an alternative to radiotherapy in patients with recurrent LGGs that have failed first-line chemotherapy.
33. Jakacki RI et al. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro-Oncology. 2011;13(8):910-5.
34. Villanueva MT. Pediatric oncology: vinblastine in low-grade glioma. Nat Rev Clin Oncol. 2012;9(5):248.
35. Khaw SL et al. Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer. 2007;49(6):808-11. (Pubitemid 47519517)
36. Gururangan S et al. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology. 2007;9(2):161-8. (Pubitemid 46580317)
37. Liu R et al. Quality of life in low-grade glioma patients receiving temozolomide. Neuro-Oncology. 2009;11(1):59-68.
38. Sutton LN et al. Long-term outcome of hypothalamic/chiasmatic astrocytomas in children treated with conservative surgery. J Neurosurg. 1995;83(4):583-9.
39. Ater JL et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(21):2641-7. This randomized controlled trial of the carboplatin/vincristine and thioguanine/procarbazine/lomustine and vincristine showed that both regimens are effective in the treatment of LGGs and the differences in the toxicity profiles may influence physician choice of treatment regimens.
40. Sie M et al. Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma? Neuropathol Appl Neurobiol. 2010;36(7):636-47.
41. Packer RJ et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791-5.
42. Hwang EI et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60(5):776-82. This study showed that antiangiogenic agents can be used in the treatment of LGGs with rapid clinical responses but however may not result in sustained stable disease.
43. Gururangan S et al. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas-a Pediatric Brain Tumor Consortium study. Neuro-Oncology. 2014;16(2):310-7. This phase II study showed that a combination of antiangiogenic agent bevacizumab and irinotecan can result in sustained disease control in some children with recurrent LGGs.
44. Avery RA et al. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111-4.
45. Nageswara Rao AA et al. Biologically targeted therapeutics in pediatric brain tumors. Pediatr Neurol. 2012;46(4):203-11.
46. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24 Suppl 1:S13-9.
47. Warren KE et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(3):324-9.
48. Gottfried ON, Viskochil DH, Couldwell WT. Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus. 2010;28(1):E8.
49. Hawkins C et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(14):4790-8.
50. Jones DT et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene. 2009;28(20):2119-23.
51. Cin H et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121(6):763-74.
52. Dougherty MJ et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro-Oncology. 2010;12(7):621-30.
53. Janzarik WG et al. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics. 2007;38(2):61-3. (Pubitemid 47434497)
54. Morita H, Nagai R. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448. Author reply 1450.
55. Farina-Sarasqueta A et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21(12):2396-402.
56. Schindler G et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397-405. This large study demonstrated the high frequency of BRAF V600E mutations in different LGGs, thereby opening up the possibility of using targeted therapy in BRAF V600E mutated tumors.
57. Horbinski C et al. Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro-Oncology. 2012;14(6):777-89.
58. Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
59. Long GV et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087-95.
60. Hauschild A et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
61. Kolar GR et al. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(3):e40-3.
62. McArthur GA et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, openlabel study. Lancet Oncol. 2014;15(3):323-32.
63. West ES, Williams VL, Morelli JG. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma. Pediatr Dermatol. 2014. doi:10.1111/pde.12316.
64. Hatzivassiliou G et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-5.
65. Heidorn SJ et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-21.
66. Sievert AJ et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A. 2013;110(15):5957-62.
67. Karajannis MA, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, et al. Phase II study of sorafenib in children with recurrent/progressive low-grade astrocytomas. Neuro-Oncology. 2012; 14(supplement 6). This phase II study showed that sorefanib may be associated with tumor progression through paradoxical ERK activation.
68. Lito P et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22(5):668-82.
69. Poulikakos PI et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387-90.
70. Prabowo AS et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol. 2014;24(1):52-66.
71. Prahallad A et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-3.
72. Rush S, Foreman N, Liu A. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(10):e159-60.
73. Kolb EA et al. Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2010;55(4):668-77.
74. Bid HK et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(24):6716-29.
75. Manning BD, Cantley LC. United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem Soc Trans. 2003;31(Pt 3):573-8. (Pubitemid 36750733)
76. Johannessen CM et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A. 2005;102(24):8573-8. (Pubitemid 40862777)
77. Jentoft M et al. Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset. Int J Clin Exp Pathol. 2010;4(1):43-57.
78. Brundage ME et al. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene. 2014. doi:10.1038/onc.2013.506.
79. Kaul A et al. Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 2012;26(23):2561-6.
80. Hutt-Cabezas M et al. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. Neuro-Oncology. 2013;15(12):1604-14.
81. Franz DN et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490-8. (Pubitemid 43358069)
82. Franz DN. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex. Biologics Targets Ther. 2013;7:211-21.
83. Krueger DA et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574-80. This study showed that everolimus is safe and effective in the treatment of SEGAs in patients 3 years and older with TS.
84. Franz DN et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125-32.
85. Kieran M, Yao X, Macy M, Geyer R, Cohen K, MacDonald T, et al. A prospective multi-institutional phase II study of everolimus (RAD001), a mTOR inhibitor, in pediatric patients with recurrent or progressive low-grade gliomas. A POETIC consortium trial. Pediatr Blood Cancer. 2013;60(S3):19. This study showed that everolimus is well-tolerated and maybe effective in the treatment of pediatric recurrent LGGs.
86. Yalon M et al. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer. 2013;60(1):71-6.
87. Saurez G et al. Clinical experience with nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev. 2009;11(3):27-33.
88. Zhang J et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602-12. Whole-genome sequencing has helped identify multiple genomic alterations in 151 pediatric LGGs and potential therapeutic targets.